Targeting xanthine oxidase degradation via PROTAC technology for the treatment of hyperuricaemia

Xue Dong; Lin Wang; Sijia Lin; Ziyi Wang; Xueyong Qi; Jin Cao; Jing Zhang; Lin Wu; Song Shen

doi:10.1039/d6tb00078a

January 1, 2026Journal of Materials Chemistry B

Targeting xanthine oxidase degradation via PROTAC technology for the treatment of hyperuricaemia

View Full Paper

Ask AI

Bookmark

Share

Key Points

The aim is to explore the potential of PROTAC technology in degrading xanthine oxidase to treat hyperuricemia.
Utilization of PROTAC technology to target and degrade xanthine oxidase
Analysis of uric acid levels pre- and post-intervention
Evaluation of systemic effects of xanthine oxidase degradation
Effective reduction of serum uric acid levels observed after treatment
Significant improvement in associated symptoms of hyperuricemia
Demonstrated potential for PROTAC as a therapeutic approach in metabolic disorders

Implication

Demonstrates targeting xanthine oxidase to reduce uric acid levels in hyperuricemia, indicating a novel therapeutic approach.

Abstract

Hyperuricemia, characterized by an elevated serum uric acid level due to the abnormal xanthine oxidase (XOD)-mediated uric acid production, is generally associated with multiple systemic disorders. In this study, XOD-targeting...

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dong et al. (2026) studied this question.

synapsesocial.com/papers/69d1fd29a79560c99a0a2fb6 https://doi.org/10.1039/d6tb00078a

View Full Paper

Ask AI

Bookmark

Share

Targeting xanthine oxidase degradation via PROTAC technology for the treatment of hyperuricaemia

Key Points

Implication

Abstract

Discussion

Cite This Study

Targeting xanthine oxidase degradation via PROTAC technology for the treatment of hyperuricaemia

Key Points

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading